Rare Diseases Constitute a ‘Public Health Issue,’ NCATS Director Warns
With 250 rare diseases newly identified every year, scientists can barely keep up — even as the healthcare system fails millions of Americans whose ... Read more
Updates
-
-
Enrollment Complete in Phase 3 Trial Testing Lenabasum in Diffuse Cutaneous SSc Patients
Enrollment has been completed in an ongoing Phase 3 clinical trial assessing the safety and efficacy of experimental therapy lenabasum in patients ... Read more -
Being Labeled a Fraud Is My Most Pressing Scleroderma Fear
I have been feeling strangely unsettled as of late. My unease is not due to the current state of the world or a nasty ... Read more -
PF Combined with Emphysema Decreases Survival Rates of Systemic Sclerosis Patients, Data Analysis Shows
Combined pulmonary fibrosis and emphysema (CPFE) impairs lung function and decreases survival rates of systemic sclerosis (SSc) patients, a retrospective analysis shows. The study ... Read more -
PALS Uplifts the Spirits of Rare-Disease Patients by Offering Free Flights
Cumbersome security procedures, rising airfares, and shrinking legroom have made commercial air travel difficult enough these days — even for healthy passengers. Imagine how ... Read more
-
Telangiectasia, Tiger Lilies, and Traditions
I always look forward to events that occur each year, particularly those involving special ... -
Corbus Changes Goal of Phase 3 Lenabasum Trial in Diffuse Cutaneous SSc, Sees as Step to Possible ‘Success’
Corbus Pharmaceuticals is adjusting the primary efficacy outcome of the ongoing and global RESOLVE-1 ... -
DEA Clears Cannabinoid-derived Active Ingredient in Investigational Scleroderma Therapy EHP-101
The U.S. Drug Enforcement Administration (DEA) has cleared the use of the active ingredient ... -
Self-talking My Way Through My Scleroderma
For years, when I was a practicing counselor, I used cognitive behavioral therapy (CBT) ... -
Rituximab Safe, Eases Skin Fibrosis in Systemic Sclerosis Patients, Study Suggests
Rituximab, an immunosuppressant antibody, alleviates skin fibrosis in patients with systemic sclerosis (SSc) and ... -
Epigenetic Changes May Be Involved in Scleroderma Development, Study Says
Epigenetic changes — chemical modifications in DNA that affect gene expression (the process by ...
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
iBio Selects Fusion Protein as Lead Candidate for New Scleroderma Treatment
News
iBio has selected a lead scleroderma treatment candidate — a molecule it calls the E4-Fc fusion protein. The company plans to continue developing it, with a goal of moving it in clinical trials in people. It also hopes ... Read more